Literature DB >> 23786938

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients.

Ying Zheng1, Guang-Yan Cai, Xiang-Mei Chen, Ping Fu, Jiang-Hua Chen, Xiao-Qiang Ding, Xue-Qing Yu, Hong-Li Lin, Jian Liu, Ru-Juan Xie, Li-Ning Wang, Zhao-Hui Ni, Fu-You Liu, Ai-Ping Yin, Chang-Ying Xing, Li Wang, Wei Shi, Jian-She Liu, Ya-Ni He, Guo-Hua Ding, Wen-Ge Li, Guang-Li Wu, Li-Ning Miao, Nan Chen, Zhen Su, Chang-Lin Mei, Jiu-Yang Zhao, Yong Gu, Yun-Kai Bai, Hui-Min Luo, Shan Lin, Meng-Hua Chen, Li Gong, Yi-Bin Yang, Xiao-Ping Yang, Ying Li, Jian-Xin Wan, Nian-Song Wang, Hai-Ying Li, Chun-Sheng Xi, Li Hao, Yan Xu, Jing-Ai Fang, Bi-Cheng Liu, Rong-Shan Li, Rong Wang, Jing-Hong Zhang, Jian-Qin Wang, Tan-Qi Lou, Feng-Min Shao, Feng Mei, Zhi-Hong Liu, Wei-Jie Yuan, Shi-Ren Sun, Ling Zhang, Chun-Hua Zhou, Qin-Kai Chen, Shun-Lian Jia, Zhi-Feng Gong, Guang-Ju Guan, Tian Xia, Liang-Bao Zhong.   

Abstract

BACKGROUND: Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease (CKD) patients are limited. The aim of the present study was to investigate the prevalence, awareness, treatment, and control of hypertension in the non-dialysis CKD patients through a nationwide, multicenter study in China.
METHODS: The survey was performed in 61 tertiary hospitals in 31 provinces, municipalities, and autonomous regions in China (except Hong Kong, Macao, and Taiwan). Trained physicians collected demographic and clinical data and measured blood pressure (BP) using a standardized protocol. Hypertension was defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, and/or use of antihypertensive medications. BP < 140/90 mmHg and < 130/80 mmHg were used as the 2 thresholds of hypertension control. In multivariate logistic regression with adjustment for sex and age, we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD patients.
RESULTS: The analysis included 8927 non-dialysis CKD patients. The prevalence, awareness, and treatment of hypertension in non-dialysis CKD patients were 67.3%, 85.8%, and 81.0%, respectively. Of hypertensive CKD patients, 33.1% and 14.1% had controlled BP to < 140/90 mmHg and < 130/80 mmHg, respectively. With successive CKD stages, the prevalence of hypertension in non-dialysis CKD patients increased, but the control of hypertension decreased (P < 0.001). When the threshold of BP < 130/80 mmHg was considered, the risk of uncontrolled hypertension in CKD 2, 3a, 3b, 4, and 5 stages increased 1.3, 1.4, 1.4, 2.5, and 4.0 times compared with CKD 1 stage, respectively (P < 0.05). Using the threshold of < 140/90 mmHg, the risk of uncontrolled hypertension increased in advanced stages (P < 0.05).
CONCLUSIONS: The prevalence of hypertension Chinese non-dialysis CKD patients was high, and the hypertension control was suboptimal. With successive CKD stages, the risk of uncontrolled hypertension increased.

Entities:  

Mesh:

Year:  2013        PMID: 23786938

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

1.  Hypertension in patients with CKD in China: clinical characteristics and management.

Authors:  Guangyan Cai; Xiangmei Chen
Journal:  Front Med       Date:  2017-09       Impact factor: 4.592

2.  Development, Reliability, and Validity of the Home Blood Pressure Monitoring Adherence Scale for Patients with Chronic Kidney Disease.

Authors:  Yamin Wang; Kun Li; Huiqun Li; Wenbo Zhao; Yanru Chen; Hongli Shang; Min Zhang; Jing Zheng
Journal:  Patient Prefer Adherence       Date:  2020-10-12       Impact factor: 2.711

3.  Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE).

Authors:  Bianling Liu; Qin Wang; Yu Wang; Jinwei Wang; Luxia Zhang; Minghui Zhao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

4.  A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease.

Authors:  Wen Zhang; Wei Shi; Zhangsuo Liu; Yong Gu; Qinkai Chen; Weijie Yuan; Yanlin Zhang; Li Gong; Rong Zhou; Mingxu Li; Hong Cheng; Jian Liu; Jun Cen; Chaoxing Huang; Yeping Ren; Peiju Mao; Changying Xing; Fuyuan Hong; Dongsheng Jiang; Li Wang; Gang Xu; Jianshe Liu; Nan Chen
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

5.  Short-Term Systolic Blood Pressure Variability and Kidney Disease Progression in Patients With Chronic Kidney Disease: Results From C-STRIDE.

Authors:  Qin Wang; Yu Wang; Jinwei Wang; Luxia Zhang; Ming-Hui Zhao
Journal:  J Am Heart Assoc       Date:  2020-06-06       Impact factor: 5.501

6.  Predicting Factors for Rapid Progressive Chronic Kidney Disease in Primary Glomerular Disease Patients with Moderate-to-Severe Stage.

Authors:  Jun Tan; Hao Zhang; Wei Zheng; Shikun Yang; Minghui Yang; Yan Liu
Journal:  Biomed Res Int       Date:  2020-11-28       Impact factor: 3.411

Review 7.  Application of Angiotensin Receptor-Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus.

Authors:  Liangying Gan; Xiaoxi Lyu; Xiangdong Yang; Zhanzheng Zhao; Ying Tang; Yuanhan Chen; Ying Yao; Fuyuan Hong; Zhonghao Xu; Jihong Chen; Leyi Gu; Huijuan Mao; Ying Liu; Jing Sun; Zhu Zhou; Xuanyi Du; Hong Jiang; Yong Li; Ningling Sun; Xinling Liang; Li Zuo
Journal:  Front Med (Lausanne)       Date:  2022-07-19

8.  The increasing financial impact of chronic kidney disease in australia.

Authors:  Patrick S Tucker; Michael I Kingsley; R Hugh Morton; Aaron T Scanlan; Vincent J Dalbo
Journal:  Int J Nephrol       Date:  2014-04-01

9.  Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL).

Authors:  Rong Lv; Jianghua Chen; Huamin Wang; Jijun Wang; Hong Cheng; Rong Li; Wei Li; Tao Zhang; Lixin Wei; Qinkai Chen; Jian Huang; Feng Yu; Shizhong Shen; Henglan Wu; Cuihong Liu; Fuyuan Hong; Jie Liu; Xiaoru Zhang; Hua Xiao; Wenbin Song
Journal:  Adv Ther       Date:  2021-07-30       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.